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Human monoclonal antibodies 447-52D and 537-
10D, both coded by the VH3 gene and specific for
the third variable region (V3) of the HIV-1 gp120,
were found to share antigen-binding structural
elements including an elongated CDR H3 forming
main-chain interactions with the N terminus of the
V3crown.However,water-mediatedhydrogenbonds
and a unique cation-p sandwich stacking allow 447-
52D to be broadly reactive with V3 containing both
the GPGR and GPGQ crown motifs, while the deeper
binding pocket and a buried Glu in the binding site of
537-10D limit its reactivity to only V3 containing the
GPGR motif. Our results suggest that the design of
immunogens for anti-V3 antibodies should avoid the
Arg at the V3 crown, as GPGR-containing epitopes
appear to select for B cells making antibodies of
narrower specificity than V3 that carry Gln at this
position.
INTRODUCTION
One way for human immunodeficiency virus type 1 (HIV-1) to
escape antibody-mediated control and eradication is by genetic
diversification of its epitopes. Designing immunogens that can
elicit broadly neutralizing antibodies able to overcome this diver-
sity remains a major challenge in developing an effective HIV
vaccine. The virus’ surface glycoprotein gp120 has five variable
regions, named V1–V5, that exhibit high sequence diversities.
Among them, V3 is relatively conserved due to its functional
importance in the life cycle of the virus—it determines the viral
co-receptor usage and viral tropism of the virus by binding to
the virus co-receptors on the cell surface, CCR5orCXCR4, a crit-
ical step in viral entry (Ivanoff et al., 1992; McKeating et al., 1989;
Resch et al., 2001; Wyatt and Sodroski, 1998). The V3 conserva-
tion is reflected both in its sequence and structure. V3 has limited
variation in length; it is almost always 35 amino acids long and it1538 Structure 17, 1538–1546, November 11, 2009 ª2009 Elsevier Lharbors at its tip a highly conserved motif: Gly-Pro-Gly-Arg/Gln
(GPGR/Q, residues 312–315 in the HXB2 numbering scheme;
Ratner et al., 1987). While the GPGR-containing V3 (V3GPGR) is
predominant in clade B viruses, V3GPGQ is more often found in
clade C and other non-clade B viruses (Kuiken et al., 1999). V3
is structurally characterized in the context of the gp120 core
(Huang et al., 2007; Huang et al., 2005). It protrudes 30 A˚
from the CD4-bound gp120 core and this extended structure
can be divided into three regions: the base, the stem, and the
crown. The conserved base is seated in the gp120 core with a
disulfide bridge (Leonard et al., 1990), while the stem extends
outwards and is flexible (Huang et al., 2005, 2007). The crown
has a unique b-conformation with the GPGR/Q turn at the distal
apex of the crown. Interestingly, all the known human anti-V3
monoclonal antibodies (mAbs) are against the crown (Gorny
et al., 1993; Zolla-Pazner et al., 2004; Zwart et al., 1991), and
studies have shown that the crown is accessible on the surface
of most HIV-1 primary isolates and serves as a neutralization
epitope (Gorny et al., 2004).
V3 is highly immunogenic and was named the ‘‘principal
neutralizing determinant’’ of HIV-1 (Javaherian et al., 1989).
Anti-V3 antibodies are found to exist in the sera of essentially
all patients infected with HIV-1 (Carrow et al., 1991; Krachmarov
et al., 2001, 2005; Vogel et al., 1994), and immunization of
animals with V3-containing immunogens can elicit anti-V3
immune responses (Javaherian et al., 1990; Law et al., 2007;
Zolla-Pazner et al., 2008). Importantly, a novel immunization
regimen combining DNA primes and protein boosts has recently
been shown to focus the rabbit immune response on the V3
epitope and elicit antibodies with cross-clade neutralization
capacities (Zolla-Pazner et al., 2008, 2009). Moreover, there are
monoclonal and polyclonal anti-V3 antibodies that display both
intra- and inter-subtype neutralization of diverse HIV strains
(Binley et al., 2004; Conley et al., 1994; Gorny et al., 1992; Krach-
marov et al., 2005). Thus, the V3 epitope is well suited as a target
for HIV-1 vaccine development (Zolla-Pazner, 2004).
Structural characterization of anti-HIV-1 human mAbs target-
ing immunogenic epitopes on the surface glycoprotein gp120
of HIV-1 can potentially facilitate the design and development
of an effective HIV-1 vaccine (Burton, 1997; Douek et al., 2006;td All rights reserved
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strategy of immunogen design requires (1) identification of
broadly reactive human mAbs, (2) determination of their struc-
tures in complex with epitopes, and (3) engineering of the struc-
tures of these epitopes onto protein scaffolds. These steps are
designed to enable scaffolded epitopes to elicit antibodies with
a breadth of neutralizing activity similar to that displayed by the
broadly reactive mAbs. Much progress has been made in identi-
fying human anti-V3 Abs, and a large number of anti-V3 mAbs
have been produced (Gorny and Zolla-Pazner, 2003; Gorny
et al., 2009).
Many anti-V3 mAbs, especially those selected from animals
immunized with V3 peptides (Goudsmit et al., 1988; Palker
et al., 1988), are considered ‘‘type specific.’’ However, a consid-
erable number of anti-V3mAbs isolated from chronically infected
human individuals and selected for specificity with V3 fusion
proteins have been found to be broadly reactive (Binley et al.,
2004; Gorny et al., 2002, 2004, 2006), displaying cross-clade
neutralizing activity against both pseudoviruses and primary
isolates (Davis et al., 2009; Gorny et al., 2002, 2004, 2006; Krach-
marov et al., 2006). Efforts have been made to understand the
origins of this broad reactivity from a genetic as well as structural
basis (Gorny et al., 2009; Stanfield et al., 2004, 2006; Stanfield
and Wilson, 2005), but many questions remain unanswered.
mAb 447-52D (IgG3, l), originally derived from an individual
infected with clade B HIV-1 (Gorny et al., 1992), is the best-
characterized human anti-V3 mAb and has been used as the
prototype of anti-V3 mAbs (Binley et al., 2004, 2008; Burton
et al., 2004; Karlsson Hedestam et al., 2008; Kwong and Wilson,
2009). Experiments have shown that 447-52D can neutralize
between 30% and 50% of HIV-1 in panels of tested primary
isolates from clades A, B, F, and H (Binley et al., 2004; Gorny
et al., 2002; Zolla-Pazner et al., 2004). However, it preferentially
neutralizes viruses that harbor the GPGR motif in the V3 crown,
with limited capacity against those with the GPGQ motif
(Cardozo et al., 2009; Davis et al., 2009; Zolla-Pazner et al.,
2004). Its neutralization potency against pseudoviruses with R
to Q mutation in the crown motif is decreased 700-fold (Krach-
marov et al., 2006). These data suggest that 447-52D is highly
specific for viruses harboring the GPGR V3 motif. The structural
basis of its antigen recognition has been investigated using both
NMR and protein crystallography, showing that 447-52D has
a highly unusual antigen-binding site (Dhillon et al., 2008; Sharon
et al., 2003; Stanfield et al., 2004). It possesses an extended
complementarity determining region (CDR) H3, which protrudes
from the body of themolecule and formsmain-chain interactions
with the N-terminal region of V3 flanking the GPGR turn. Further-
more, the antigen-binding site has a unique structure that forms
a three residue cation-p stacking that sandwiches the Arg side
chain of the GPGR motif. Although 447-52D has poor or no
neutralizing activity against viruses bearing the GPGQ V3 motif,
it is able to bind V3 peptides with the GPGQ motif (Gorny et al.,
2002; Zolla-Pazner et al., 2004). The structural details of how the
active site of 447-52D interacts with V3 containing the GPGQ
motif remain unclear.
Human mAb 537-10D (IgG1, l) is genetically related to
447-52D; it is also coded by the VH3 Ig gene family: 447-52D
and 537-10D use the VH3-15 and VH3-7 Ig gene segments,
respectively (Gorny et al., 1993, 2009). Thus, the two antibodiesStructure 17, 1538–154are highly homologous in their amino acid sequence. Like
447-52D, 537-10D also possesses a long CDR H3 loop that is
20 amino acids in length [Kabat numbering (Kabat et al.,
1991)]. However, 537-10D has a much narrower breadth of reac-
tivity and a lower potency of neutralization; it is known to only
neutralize HIV-1 strains MN and BaL (both harboring the GPGR
motif), with a potency 50 times less than that of 447-52D (Gorny
et al., 1992, 1993, 2004). The structural basis for this narrower
reactivity and reduced potency is not yet understood.
A structural comparison of homologous human mAbs derived
from similar genetic origins but with very different antigenic prop-
erties would help to further our understanding of the structural
basis of antigen recognition and potentially advance HIV-1
vaccine development by facilitating the design of immunogens
that can induce broadly neutralizing antibodies against the V3
region of gp120 (Zolla-Pazner, 2005). We have therefore exam-
ined the structural differences between these two homologous
antibodies by crystallizing Fab fragments of 447-52D and 537-
10D in complex with V3 peptides carrying the GPGQ and
GPGR motifs, respectively.
RESULTS
Breadth of Reactivity of mAbs 447-52D and 537-10D
Measured by ELISA
Despite the sequence similarities between mAbs 447-52D and
537-10D (Figure 1A; see Figure S1 available online), they were
previously shown to display different binding affinities to V3
peptides and different patterns of peptide cross-reactivity and
virus-neutralizing activity (Gorny et al., 1992, 1993, 2004). To
systematically test their reactivity against different V3s, we
measured their binding reactivity by enzyme-linked immunosor-
bent assay (ELISA) with a panel of 24 V3 peptides representing
a wide range of virus isolates from clades A, B, and C (Figure 1B).
The 447-52D antibody was able to bind peptides containing both
theGPGRandGPGQmotifs,while the537-10Dshowedabinding
pattern restricted to the former. Thus, mAb 447-52D exhibited
broad reactivity, binding 22/24 V3 peptides, including those from
clades A, B, and C (the two nonreactive peptides, CM1.CA7 and
UR29, have amino acid sequences unusual in HIV-1 strains at the
b turn of the V3 loop). In contrast, mAb 537-10D had a much nar-
rower pattern of reactivity, only reacting with peptides containing
the GPGR apex motif (Figure 1B). Therefore, although anti-V3
mAbs 447-52D and 537-10D have considerable sequence simi-
larities, they display very different reactivity profiles.
Structure of the Fab Fragment of mAb 447-52D
in Complex with a V3GPGQ Peptide
To understand howmAb 447-52D binds V3GPGQ, we determined
the crystal structure of the Fab fragment of 447-52D in complex
with a 23-mer peptide derived from a clade A virus strain,
W2RW020 (V3W2R), containing the GPGQ motif. The structure
was refined to 2.25 A˚ resolution (Figure 2A and Table 1; Fig-
ure S2A). There are two Fab/V3W2R complexes in the crystallo-
graphic asymmetric unit, but they were highly similar, with a
root mean square deviation of less than 0.6 A˚ when superim-
posed. For clarity, we will therefore refer to only one of the
Fab/V3 complexes. We will follow the Kabat and Wu convention
(Kabat et al., 1991) for numbering of the heavy and light chains6, November 11, 2009 ª2009 Elsevier Ltd All rights reserved 1539
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Structural Comparison of Anti-V3 mAbspreceded by ‘‘H’’ and ‘‘L,’’ respectively, and designate the resi-
dues of the V3 peptide with a ‘‘P’’ and the residue number. Resi-
dues P305 to P316 of the V3 crown region, with the sequence
KGVRIGPGQA, were observed to have strong electron densities
and have thus been built into the final model. There was no
visible electron density after AlaP316, reflecting additional flexi-
bility of the C terminus of V3 in this complex in comparison
with the previous mAb 447-52D Fab/V3 peptides structures
(Dhillon et al., 2008; Stanfield et al., 2004), of which up to three
additional residues were visible at an electron density contour
level of 0.7 s.
The position and orientation of the V3W2R peptide in the
complex is very similar to that observed for the structures of
447-52D/V3GPGR complexes reported previously (Dhillon et al.,
2008; Stanfield et al., 2004). The antigen-binding site adopts
a shape similar to a soup ladle (Figures 2A and 2C). The ‘‘handle’’
of the ladle is formed by the elongated b hairpin structure of the
CDR H3 loop extending out from the body of the mAb, while
the ‘‘bowl’’ is formed by the base of CDR H3 together with the
other CDR loops (Figure S2A). The fiveN-terminal residues flank-
ing the apex of V3 form an anti-parallel three stranded b sheet
together with the hairpin of the CDR H3 (Figures 2A and 3A;
Figure S2A). There are four hydrogen bonds between the
main-chain backbones of CDR H3 and the N-terminal side of
V3 flanking the apex turn; this is similar to previously described
447-52D/V3GPGR structures (Dhillon et al., 2008; Stanfield et al.,
2004) (Figure 3A; Table S1A). There is also a side chain-specific
Figure 1. 447-52D and 537-10D: Sequences
of the Variable Fragments and Cross-Reac-
tivity with V3 Peptides
(A) Protein sequence alignments of the variable
regions for both heavy and light chains of
447-52D and 537-10D. Boxes indicate the CDR
regions (Kabat definition), while asterisks and
arrowheads mark the residues making direct or
water-mediated interactions in the reported struc-
tures with the V3 epitopes, respectively. TrpH47
(arrow) of 537-10D has direct contacts with the
epitope, although it is not in any of the CDR loops
(see Figures 2B and 4B). Note multiple Tyr resi-
dues in CDR H3 of both mAbs.
(B) The ELISA reactivities of 447-52D and 537-10D
against a panel of V3 peptides (sorted according
to their ELISA measurements). Only sequences
corresponding to the regions of V3 in the struc-
tures that have direct contacts with the antibodies
are shown (9 amino acids for 447-52D and 11 for
537-10D), and they are numbered at the bottom
in the HXB2 numbering scheme. The colors depict
the sequence similarities. Note that 447-52D
reacts with both V3GPGR and V3GPGQ peptides,
while 537-10D only reacts with V3GPGR.
interaction between the hydroxyl group
of CDR H3 residue TyrH100J and the side
chain of ArgP308, analogous to the
TyrH100J-HisP308hydrogenbondobserved
for the 447-52D/V3GPGR structures (Dhil-
lon et al., 2008; Stanfield et al., 2004).
Four consecutive tyrosine residues in the
heavy chain CDR H3 on the b strand facing V3 provide an
extended surface area for binding (Fellouse et al., 2004). Two of
these, TyrH100G and TyrH100I, together with TyrL32 from the light
chain, interact with ValP307 and IleP309, two V3 positions usually
occupied by hydrophobic residues Ile/Val (Kuiken et al., 1999).
Theanti-parallel configuration of theCDRH3andV3 loopb strand
orients the V3 b turn into the 447-52D ladle, where three residues
from the light chainCDRL2 loop, TrpL91, AlaL95B, andTrpL96, form
an 90 corner for the docking of the GlyP312-Pro P313-GlyP314
turn of the V3 apex (Figures 2A and 4A). Here, the pyrrolidine
ring of ProP313 is placed parallel to the indole ring of the antibody
residue TrpL91 with a distance of 3.6 A˚ between the aromatic
planes (Figure 4A).
The principal difference between the 447-52D Fab/V3W2R
structure and the previously determined Fab/V3GPGR complexes
(Dhillon et al., 2008; Stanfield et al., 2004) lies in the interactions
between the antibody and the side chains of the ArgP315/GlnP315
of the GPGR/Q motif (Figures 4A, 5A, and 5B; Figure S3). In the
447-52D/V3GPGR structures, mAb 447-52D uses the residues
TrpH33, AspH95, and TyrH100J to make highly unusual specific
interactions with ArgP315. The guanidinium moiety of ArgP315 is
sandwiched between the indole ring of TrpH33 and the phenyl
ring of TyrH100J to form a rare three residue cation-p stacking.
In addition, ArgP315 is positioned so that its side chain can form
a salt bridge with AspH95 (Figure S3) (Dhillon et al., 2008;
Stanfield et al., 2004). In our 447-52D Fab/V3W2R structure, the
shorter GlnP315 is unable to form a cation-p interaction with the1540 Structure 17, 1538–1546, November 11, 2009 ª2009 Elsevier Ltd All rights reserved
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Structural Comparison of Anti-V3 mAbsTrpH33 and TyrH100J and is too far away to form a direct hydrogen
bond with AspH95 (Figures 4A, 5A, and 5B). Instead, GlnP315
forms a water-mediated hydrogen bond with the side chain of
AspH95, resulting in a 30% decrease in the buried area at the
Fab/V3 interface relative to the mAb interactions with the
GPGR sequence (Table S2A).
Interestingly, in addition to the AspH95 that is buried in the deep
center of the binding site, there are two additional charged
residues at the 447-52D binding site, ArgH50 and AspH58, with
Figure 2. Structures of Fab 447-52D/V3W2R and Fab 537-10D/V3MN
Complexes
(A) Stereoview of the 447-52D/V3W2R complex.
(B) Stereoview of the 537-10D/V3MN complex. The Fab light chain and heavy
chain and the V3 peptide are colored cyan, green, and magenta, respectively.
Side chains of the residues of the antibodies that have direct contacts with the
V3 epitopes are shown.
(C and D) The mAbs 447-52D (C) and 537-10D (D) are shown as surface
representations to illustrate the ladle shape of the binding sites. Note that
the bowl part of the 447-52D binding site, with an additional spout (arrow), is
much shallower than that of 537-10D.Structure 17, 1538–154the latter placed at the very outer edge of the binding site
(Figures 4A, 5A, and 5B). ArgH50 in the middle of this chain of
negatively-positively-negatively charged residues forms, on one
side, an intra-molecular salt bridge with AspH58 and, on the other
side, a water-mediated hydrogen bond with AspH95 (which
forms a salt bridge with ArgP315 of V3 in the 447-52D/V3GPGR
structures). This water molecule is tightly bound at the bottom
of the antigen-binding site and is coordinated tetrahedrally by
the side chains of AsnH35, ArgH50, AspH95, and TrpL96 (Figure 5B).
Structure of the Fab Fragment of mAb 537-10D
in Complex with a V3GPGR Peptide
In order to compare the structures of the broadly reactive 447-
52D with that of a ‘‘type-specific’’ human mAb, we determined
the structure of Fab 537-10D in complex with a 23-mer peptide
corresponding to the clade B viral isolate MN (V3MN), a GPGR-
containing V3, and refined it to 2.4 A˚ resolution (Figures 2B
and Table 1; Figure S2B). There was only one Fab/V3MN complex
in the crystallographic asymmetric unit, and we again labeled the
V3 peptide and the antibody heavy and light chains with residue
numbers preceded by P, H, and L, respectively. Strong electron
densities were found for 15 amino acids in the V3 peptide (P304
to P320) with sequence RKRIHIGPGRAFYAT and were built into
Table 1. X-ray Diffraction Data and Refinement Statistics
447-52D/V3W2R 537-10D/V3MN
Crystal features
Space group P21 P21
Unit cell dimensions a = 70.27 A˚ a = 46.36 A˚
b = 76.21 A˚ b = 71.32 A˚
c = 113.92 A˚ c = 77.12 A˚





Wavelength (A˚) 0.9791 0.9790
Resolution (A˚) 2.25 2.4
Total observations 428365 115181
Unique reflections 56738 18997
Completeness (%) 99.9 (99.4) 97.9 (86.3)
I/s (I) 18.6 (4.6) 15.3 (2.0)
Rsym (%) 8.8 (48.5) 8.0 (33.1)
Model quality
Rcryst(%) 19.6 18.7
Rfree (%) 23.2 24.1
Total residues 921 455
Water molecules 551 322
Mean B value (A˚2) 32.2 30.9
Rmsd for bond lengths (A˚) 0.006 0.006
Rmsd for bond angles () 1.38 1.36
Ramachandran plot (Procheck)
Most favored regions (%) 88.6 88.3
Allowed regions (%) 10.9 10.4
Generously allowed (%) 0.3 0.3
Outlier regions (%) 0.3 1.06, November 11, 2009 ª2009 Elsevier Ltd All rights reserved 1541
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similar to that of the Fab 447-52D/V3W2R complex (Figure 2;
Figure S2), permitting again the use of the soup ladle analogy
for its antigen-binding site. The comparable shape of the two
mAb binding sites is determined by the related Ig genes coding
for the variable fragments (see Figure S1). However, the bowl of
the 537-10D binding site is considerably deeper, measuring
about 6 A˚ in depth (Figure 2D), in contrast to the 2 A˚ depth of
the 447-52D antigen-binding site (Figure 2C). This deeper bowl
allows for the complete burial of the apex GPGR of the V3MN
peptide, except the carbonyl oxygen of GlyP314 that is pointing
outward.
mAb 537-10D CDR H3 forms six main-chain hydrogen bonds
with the N-terminal strand of the V3MN peptide (Figure 3B; Table
S1B), which is one and two more than observed for the 447-52D
Fab/V3MN and the Fab/V3W2R crystal structures, respectively
(Figure 3A; Dhillon et al., 2008; Stanfield et al., 2004). Together
with the C-terminal region flanking the V3 apex, V3 in 537-10D
forms a well-ordered four stranded anti-parallel CDR H3/V3
b sheet, rather than the three stranded sheet observed for
447-52D (Figure 3). Like 447-52D, interactions are also observed
in the 537-10D/V3MN with residues Ile
P307 and IleP309 (the highly
conserved hydrophobic positions) and at the GlyP312-Pro P313-
GlyP314 turn of the crown. There are five tyrosine residues in
Figure 3. Main-Chain Interactions
(A and B) Main-chain interactions between V3 peptide and CDR H3 in the
447-52D/V3W2R (A) and 537-10D/V3MN (B) complexes. The CDR H3 (green)
and V3 (magenta) interactions of the 447-52D and 537-10D Fab/V3 structures
are shown as ribbons (top panels) as well as with detailed hydrogen bonds
(lower panels).1542 Structure 17, 1538–1546, November 11, 2009 ª2009 Elsevier Lthe 537-10D CDR H3, including the conserved TyrH100G and
TyrH100I residues that, together with TyrL32, provide a hydro-
phobic surface for interaction with the hydrophobic IleP307 and
IleP309 residues. The GlyP312-Pro P313-GlyP314 turn of the V3
crown is docked into a hydrophobic, non-polar corner formed
by ValL96, TrpH47, and MetH100L (Figures 2B and 4B). Interest-
ingly, TrpH47 interacts directly with the V3 epitope, although it
does not belong to any of the CDR loops (Figure 1A), contrary
to the common perception that only residues in the CDR loops
interact directly with epitopes.
mAb 537-10D’s interactions with the key residue ArgP315 of the
V3 crown are similar to those of mAb 447-52D (Figure 4; Fig-
ure S3). Residues TrpH33 and TyrH100J that sandwich ArgP315 in
447-52D are conserved in 537-10D. The guanidinium moiety of
ArgP315 stacks closely (3.2 A˚) and almost parallel to the indole
ring of the TrpH33 of 537-10D to allow a two residue cation-p
stacking. However, there are some crucial differences. First, in
contrast to 447-52D, the phenyl ring of TyrH100J is not able to
sandwich ArgP315 on the other side. Instead, it is tilted 60 and
displaced to the side (Figure 4B). Second, although ArgP315
forms a salt bridge (2.72 A˚) with the negatively charged GluH95,
a residue that is homologous to, but has a longer side chain
than, the AspH95 of 447-52D, the salt bridge is completely buried
at the 537-10D/V3 interface due to the deeper binding site.
Furthermore, different from 447-52D, there are no alternately
charged residues and mediating water molecules at the bottom
of the 537-10D binding site.
DISCUSSION
The genetic origin of a human anti-V3 mAb may correlate with its
capacity to neutralize HIV-1 viruses (Gorny et al., 2009), and we
present here a structural comparison of two genetically related
human anti-V3 mAbs: the broadly reactive 447-52D and the
narrowly reactive (or ‘‘type-specific’’) 537-10D, both encoded
by VH3 gene but with very different spectra of cross-reactivity
(Figure 1). Our structures show that they do have highly similar
antigen-binding sites, shaped like a soup ladle, with three key
structural determinants (Figure 2). (1) The long CDR H3—the
handle of the ladle—binds to the V3 epitope through main-chain
interactions (Figures 2 and 3). The long tyrosine-lined CDR H3
loop extends 25 A˚ away from the body of the antibody and
interacts with the N-terminal end of the V3 crown. (2) The hydro-
phobic corner—the left half of the ladle’s bowl—interacts with
the GlyP312-ProP313-GlyP314 turn of the V3 crown (Figure 4). (3)
The polar/charged corner—the right half of the bowl—interacts
specifically with the side chain of residue ArgP315/GlnP315 of V3
(Figures 4 and 5; Figure S3). The fact that a negatively charged
residue, AspH95 in 447-52D and GluH95 in 537-10D, resides at
the base of this binding corner, which can form a salt bridge
with the side chain of ArgP315 of the V3 epitopes indicates that
both mAbs are specific for V3 containing the GPGR motif, or
V3GPGR. This is consistent with the fact that both mAbs were
derived from patients infected with clade B viruses, within which
the V3GPGR is predominant (Gaschen et al., 1999).
The structural details of the three epitope-binding determi-
nants of 447-52D and 537-10D can explain the breadth of their
cross-reactivities against V3 peptides as measured by ELISA
(Figure 1B). Both mAbs have a long protruding CDR H3 thattd All rights reserved
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with the N-terminal side of the V3 loop flanking the b turn; hence
they can tolerate sequence variations in this region of the V3
crown. mAb 447-52D binds V3GPGQ peptides in addition to
V3GPGR peptides (Figures 1B, left panel) because the apex
residue GlnP315 can interact with the antibody through water-
mediated hydrogen bonds. However, the relative affinity
measured by 50% maximal binding in ELISA of 447-52D with
V3GPGQ peptides (data not shown) is lower than with the
V3GPGR peptides, as V3GPGQ can not form the salt bridge nor
the unique cation-p sandwich stacking. In contrast, mAb 537-
10D can only bind V3GPGR peptides (Figure 1B, right panel)
because the buried negatively charged GluH95 at its binding
site must be paired with the positively charged ArgP315.
Our structural data also provide clues for understanding the
substantial differences in epitope binding, in terms of KD values,
between 447-52D and 537-10D (Table S3A). The V3-binding
affinities of these two antibodies are known to be quite different:
the binding affinity of 537-10D is many times lower than that of
447-52D measured for six V3 peptides (Gorny et al., 1993). The
higher affinity of 447-52D against V3GPGR peptides may be
Figure 5. Water-Mediated Interactions at
the Antigen-Binding Site
(A) Electron densities (the 2Fo–Fc map contoured
at 1.2 s level) around a well-coordinated water
(water 1) molecule at the base of the antigen-
binding site in the 447-52D/V3W2R complex.
(B) Water-mediated hydrogen-binding networks in
the 447-52D/V3W2R complex. Note that water 1 is
coordinated tetrahedrally by the side chains of
four surrounding residues. This water molecule is
also present in the 447-52D/V3GPGR complexes
(see Figure S3). Note also that GlnP315 does not
interact directly with AspH95 but is mediated by
another water molecule (water 2).
Figure 4. Structural Details of the Epitope-
Binding Around the Apex of the V3 Crown
in Fab 447-52D/V3W2R and Fab 537-10D/
V3MN Complexes
(A) Stereoview of the 447-52D/V3W2R complex.
(B) Stereoview of the 537-10D/V3MN complex.
Note the two water molecules (water 1 and 2) at
the antigen-binding site of 447-52D. Also note
that TrpH47, a non-CDR residue, has direct contact
with the epitope in 537-10D.
attributed to two of its three epitope-
binding determinants: the hydrophobic
corner and the cation-p stacking that
sandwiches the side chain of ArgP315. In
the former determinant, 447-52D appears
to have an ideal shape for the GPG turn:
a square corner formed by mAb residues
TrpL91, AlaL95B, and TrpL96, which fits
perfectly the peptide plane formed by
GlyP312 and the pyrrolidine ring of
ProP313 of the V3 GPG turn (Figure 4A).
In the latter determinant, 447-52D can
sandwich the guanidinium group of ArgP315 by a unique three
residue cation-p interaction stacking, while 537-10D can only
provide half of that (a two residue stacking).
The difference in neutralizing capacity between the two mAbs
(Table S3B) is a more complex issue. First, the neutralization
capacity of 537-10D is narrower than that of 447-52D; it only
neutralized two of the seven viruses (all with the GPGR motif)
tested. This may be attributed to the more restrictive antigen-
binding site of 537-10D, i.e., the structurally shallow antigen-
binding site of 447-52D can better tolerate flexibility of the V3
crown, while the deep pocket of 537-10D requires a ‘‘closer
fit’’ in order to bind (Figure 2 and Table S2). Second, for the
two viruses that both can neutralize, the 50% neutralizing dose
of 537-10D for HIV-1MN isolates was 54 times that of 447-52D
as reported in one study and 17-fold in another previous study
(Gorny et al., 1992, 1993). The origin of this difference may lie
in the binding kinetics of these two mAbs in neutralization. The
charge states of the negatively charged residue (AspH95 for
447-52D and GluH95 for 537-10D) in the binding pockets of the
two antibodies are likely very different before the epitope
approaching the binding site. In the case of 537-10D, GluH95 atStructure 17, 1538–1546, November 11, 2009 ª2009 Elsevier Ltd All rights reserved 1543
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cules before epitope binding. These solvent molecules have to
be stripped awaywhen V3 binds, likely slowing down the binding
kinetics. In contrast, AspH95 of the 447-52D antigen-binding site
is hydrated by a stably bound water molecule, which is not
removed by epitope binding. (This water molecule was also
present in the previous 447-52D/V3GPGR complexes although
it was not discussed.) In addition, the bowl of 447-52D has
a ‘‘spout’’ (Figure 2C), which can ‘‘leak out’’ any additional
solvent molecules upon epitope binding.
The insights gained through the structural understanding of
the antibody-antigen interactions of human anti-V3mAbs should
contribute to the rational design of immunogens that will elicit
broadly neutralizing antibodies (Zolla-Pazner, 2005). The struc-
tures of 447-52D and 537-10D in complex with V3 peptides
show that two of the three structural determinants—the long
CDR H3 making main-chain interactions with the N terminus of
V3 crown and the docking of the relatively conservedGPG region
of the V3 crown—can maximally tolerate the sequence variation
that occurs in the central portion of the V3 loop. However, the
third structural element of these two antibodies—the polar/
charged corner of the binding pocket—imposes limitations on
their specificities. B cells making antibodies with this charged
pocket appear to be preferentially selected by V3 epitopes that
contain ArgP315 at the tip of the V3 crown, giving rise to anti-V3
antibodies that are less broadly reactive than those induced by
viruses carrying V3 epitopes that contain GlnP315 (Krachmarov
et al., 2005; Gorny et al., 2006). Structurally, there seem to be two
families of anti-V3 human antibodies: one family binds squarely
on the GPGR/Q motif (such as 447-52D and 537-10D), while
the other family avoids this motif (such as 2219). The presence
of Arg draws immune response to this motif, and GPGR-contain-
ing epitopes tend to elicit antibodies belonging to the first family.
Although 447-52D is broadly reactive, its antigen-binding site
possesses rare structural determinants highly optimized for
binding the GPGR motif and capable of tolerating sequence
variation and flexibility of the epitopes. The chance of eliciting
antibodies like 447-52D is hence small. It follows that immuno-
gens mimicking V3 neutralization epitopes that do not contain
ArgP315 may be more advantageous than those that bear
ArgP315. Undoubtedly, a successful V3-based vaccine will have
to mimic several canonical V3 conformations representing V3
structures that are recognized by broadly neutralizing antibodies
such as 447-52D and 2219 (Stanfield et al., 2006) and F425-b4e8
(Bell et al., 2008). Comparison of the structure of these anti-V3
mAbs to those of mAbs with narrow specificity, like 537-10D,
will contribute to the design of better V3 epitopes useful in
inducing broadly neutralizing antibodies.
EXPERIMENTAL PROCEDURES
Antibody Production, Sequencing, and Fab Preparation
Human mAbs 447-52D and 537-10D were produced as previously described
(Gorny et al., 1989). Briefly, peripheral blood mononuclear cells derived from
HIV-1-infected individuals were transformed with Epstein-Barr virus, and the
cells reactive with a 23-mer V3MN peptide were fused with heteromyeloma
cells, SHM-D33 (Teng et al., 1983). The resulting hybridomas were cloned
by limiting dilution tomonoclonality. mAbs 447-52D and 537-10Dwere purified
from culture supernatants on protein G and protein A columns (GEHealthcare),
respectively.1544 Structure 17, 1538–1546, November 11, 2009 ª2009 Elsevier LThe nucleotide sequences of the variable fragments of the heavy and light
chains of mAb 447-52D and the heavy chain of mAb 537-10D were taken
from published data (Gorny et al., 2009; Lewis et al., 1995). The 537-10D light
chain variable fragment was sequenced using cDNA prepared from previous
studies (Gorny et al., 2009). A combination of two methods was used: 50
RACE amplification of cDNA ends (Invitrogen) and TOPO TA cloning method
(Invitrogen). Briefly, using the 50RACE method poly-C tails were added to 30
ends of the cDNA with terminal deoxynucleotidyl transferase followed by
PCR amplification using 50RACE Abridged Anchor primer and reverse primer
specific for the constant domain of the l light chain gene (50-CACTGTCTT
CTCCACGGTGCTCCCTTC-30). Then, PCR products were directly cloned
into a PCR 2.1-TOPO vector. Clones were verified by enzyme mapping. Six
colonies were selected and digested with EcoRI. The plasmids with correct
insert size were sequenced at the institutional DNA Sequencing Facility. The
sequence data were analyzed using the International ImMunoGeneTics
(IMGT) information system (http://imgt.cines.fr).
To produce the antigen-binding fragments (Fabs), papain (Worthington) in
100 mM sodium acetate (pH 5.5) was activated with 10 mM cysteine and incu-
bated with the mAbs at a 1:20 molar ratio for 4 hr at 37C. Papain was then
deactivated using iodoacetamide and the Fabs were then purified with protein
G (for 447-52D) or protein A (for 537-10D) columns. The Fabs were further
purified by size exclusion chromatography after dialysis overnight against
50 mM sodium acetate (pH 5.5)/100 mM NaCl.
V3 Peptide Panel
Twenty-four 19- to 24-mer peptides that span the crown of the V3 region from
group M (clade A, B, and C) HIV-1 viruses were used. Five V3 peptides repre-
senting the sequences of RF, SF2, NY/5, CDC4, and WM52 were purchased
from Intracel, Inc.. Four peptides, MN, BZ167, SF162, and VI191, were
synthesized by Sigma-Genosys. Three peptides, D687, D808, and D757,
were synthesized by Genemed Biotechnologies and peptide W2RW020 was
synthesized by Macromolecular Resource. The remaining peptides were
synthesized by L. Loomis-Price at the H.M. Jackson Foundation by standard
solid-phase methods using an ABI 433 automated peptide synthesizer and
were >70% pure as assessed by HPLC.
ELISA
The reactivity of 447-52D and 537-10D against a panel of V3 peptides derived
from various clades wasmeasured by ELISA. Briefly, ELISA plates were coated
overnight at 4C with V3 peptides at 1.0 mg/ml. The plates were washed three
times with phosphate buffered saline (PBS) with 0.05% Tween-20 (pH 7.4)
(PBST) and incubated with mAbs at a concentration of 10 mg/ml for 1.5 hr at
37C.Theplateswerewashed to removeanyunboundantibodiesand incubated
with alkaline phosphatase-conjugated goat anti-human IgG (Southern Biotech)
for 1.5 hr at 37C. The plates were then washed three times with PBST, the
substrate (p-nitrophenyl phosphate in 10% diethanolamine) was added, and
color was read at 405 nmafter 30min incubation at room temperature. Negative
controls consisted of V3 peptide-coated wells reacted with an irrelevant human
anti-parvovirusB19mAb1418 (Gigler etal., 1999); cut-off valuesweredefinedas
the mean plus 33 SD obtained from three negative control wells.
Crystallization, Data Collection, Structure Determination,
and Refinement
Commercially synthesized 23-mer V3 peptides corresponding to clade A strain
W2RW020, with amino acid sequence NNTRKGVRIGPGQAFYATGGIG
(V3W2R), and clade B strain MN, with amino acid sequence YNKRKRIHIGPG
RAFYTTKNIIG (V3MN), were dissolved in water to 1 mg/ml and added in a
5:1 molar ratio to purified Fab fragments of 447-52D and 537-10D, respec-
tively. The mixtures were then concentrated to 16 mg/ml for crystallization.
Conditions for crystallization were screened with the hanging drop method
and initial crystals for both complexes were observed within 48 hr. Well dif-
fracted crystals were obtained in 2–3 weeks. The 447-52D/V3W2R complex
was crystallized with a well solution of 1.4 M ammonium sulfate and 0.1M
Tris (pH 7.5), and the 537-10D/V3MN complexwith 20%PEG4000, 5%2-prop-
anol, and 0.1 M HEPES (pH 7.5).
Selected crystals were briefly soaked in their respective mother liquor with
additional 25%glycerol (v/v) prior tomounting onto the X-ray beam. Diffraction
data were collected at beamlines X4A and X4C, National Synchrotron Lighttd All rights reserved
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Structural Comparison of Anti-V3 mAbsSource, Brookhaven National Laboratory. All data sets were processed using
the HKL package (Otwinowski and Minor, 1997), and structures were deter-
mined in CNS (Brunger et al., 1998) by molecular replacement using the
447-52D Fab/V3MN structure (Protein Data Bank entry 1Q1J) as the starting
model. Cycles of refinement for each model were carried out in CNS and O
(Jones, 2004). Non-crystallographic symmetry restraints were used in the early
stage of the structural refinement for the 447-52D Fab/V3GPGQ W2R model.
Final structural analysis was carried out using ICM (Abagyan et al., 1994),
and figures were generated using PyMOL (DeLano, 2002) and ICM.
ACCESSION NUMBERS
The atomic coordinates of both structures have been deposited in RCSB
Protein Data Bank with PDB IDs 3GHB (447-52D/V3W2R complex) and 3GHE
(537-10D/V3MN complex).
SUPPLEMENTAL DATA
Supplemental Data include three figures and three tables can be found
with this article online at http://www.cell.com/structure/supplemental/
S0969-2126(09)00380-3.
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